id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-266455-rbblg4pu	Poole, Stephen	Rapid syndromic molecular testing in pneumonia: The current landscape and future potential	2019-12-03		.txt	text/plain	4839	232	35	Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. This is an FDA approved and CE marked platform that uses nested real-time PCR to detect 34 clinically important respiratory targets (15 semi-quantitative bacterial targets, 3 qualitative atypical bacterial targets, 8 [30] [31] [32] Furthermore, the pneumonia panel detects pathogens in a much higher proportion of samples than culture. Rapid syndromic molecular platforms have the potential to significantly improve the use of antibiotics and clinical outcomes in patient with pneumonia, but high quality randomised controlled trials are urgently required to evaluate their clinical impact. an observational study comparing the performance of two multiplex PCR platforms against routine microbiology for the detection of potential pathogens in patients with suspected hospital acquired/ventilator associated pneumonia (HAP/VAP) across	./cache/cord-266455-rbblg4pu.txt	./txt/cord-266455-rbblg4pu.txt